

Supporting Information

Synthesis of Biologically Important Tetrahydroisoquinoline (THIQ) Motifs using Quantum Dot Photocatalyst and Evaluation of Their Anti-Bacterial Activity

Jiteshkumar P. Deore, Mrinmoy De*

Department of Organic Chemistry, Indian Institute of Science, Bengaluru 560012

Email: md@iisc.ac.in

Table of Contents

1. General Information
2. Synthesis and Characterization of Quantum Dots
3. Optimization of reaction condition
4. Antibacterial assay
5. Recyclability of Catalyst
6. Unsuccessful Substrates
7. General Procedure for synthesis of C1 substituted THIQ
8. Procedure for reaction scale up
9. Photograph of reaction setup
10. Characterization of Substrates
11. NMR and HRMS copies

1. General Information

Unless otherwise indicated, all reagents and solvents were purchased from commercial distributors and used as received. THF was dried over sodium/benzophenone then distilled and stored under Ar gas for moisture sensitive reactions. Column chromatography was performed with silica gel (200 - 300 mesh). Thin layer chromatography (TLC) was measured on silica gel 60 F254 and was visualized under ultraviolet light (254 nm and 365 nm). NMR spectra were recorded on Bruker Avance operation, ^1H at 400 MHz & ^{13}C at 100MHz. All chemical shifts are given in ppm downfield relative to Tetramethylsilane (TMS) and were referenced to TMS as internal standard¹. ^1H NMR chemical shifts are designated using the following abbreviations as well as their combinations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad signal. NMR data were processed using the TopSpin 3.6.2 software package. High resolution mass spectra (HRMS) were obtained on Waters Xevo G2-XS Q-TOF equipped with ESI.


All visible light mediated reactions were carried out in 10 ml cylindrical Schlenk tube to get maximum exposure to light source. Blue LED of 10 W were used as light source for 420 nm. The distance from the Blue LED to the irradiation vessel maintain approx. 5 cm. No filter was used in the light-promoted reactions. During reactions, oxygen atmosphere was maintained through normal oxygen filled balloon.

Abbreviations:


EtOAc: ethyl acetate; MeCN: Acetonitrile; PTSA: p-Toluenesulfonic acid; DCM: dichloromethane; MeOH: methanol; THF: tetrahydrofuran; Et₂O: diethyl ether; Me: methyl; Et: ethyl; Bn: benzyl.

2. Synthesis and Characterization WS₂ Quantum Dots


In the laboratory, we prepared a suspension of WS₂ in N,N-Dimethylformamide (DMF) through a solution process. Initially, we added 10 mg of WS₂ to 2.5 mL of DMF and subjected the mixture to sonication for 5 hours. After that, we centrifuged the mixture at 8000 rpm for 20 minutes at room temperature to remove any remaining WS₂ flakes. The obtained suspension was then transferred to a Teflon-lined stainless-steel autoclave and maintained at a temperature of 200 °C for 10 hours. It was then naturally cooled to room temperature. To purify the QD solution, we centrifuged the crude solution at 12000 rpm to separate the bulk material, and collected the QD in the supernatant. Finally, the collected QD in DMF was dried under reduced pressure using a rotary evaporator, dispersed in water, and stored under nitrogen.



1a. TEM image



1b. Absorption spectra



1c. Emission spectra

Figure S1. Characterization of MoS₂ QD (TEM, Absorption & Emission spectra).


3. Optimization of reaction condition

After stirring for respective time at rt, reaction mixture was portioned between water layer (10 mL) and EtOAc layer (10 mL). The aqueous layer was extracted with EtOAc (10 mL x 3 times), and the combined organic phase was washed with a saturated solution of brine (10 mL), the combined organic layer was dried over anhydrous Na₂SO₄, concentrated to afford the residue. Obtained crude residue was recorded for NMR in CDCl₃ solvent. Yields and conversions were calculated from signal ratios relative to the internal standard Terephthalaldehyde.

4. Antibacterial assay

The antimicrobial efficacy of synthesized compounds was evaluated against Methicillin-Resistant *Staphylococcus aureus* (MRSA, USA300) representing Gram-positive bacteria. The frozen bacteria were reactivated on nutrient agar plates. A small number of bacterial colonies were then cultured in Luria broth media (LB, HiMedia – 20 g/L) overnight for approximately 10-12 hours to establish the primary culture. Subsequently, a secondary culture was initiated by transferring 50 µL from the primary culture into 5 mL of fresh LB media, allowing it to reach the mid-log growth phase (A_{600nm}~0.3). For experimental purposes, the optical density (OD) was adjusted to A_{600nm}=0.01, resulting in a bacterial concentration of ~10⁶ bacterial/mL.

The microbroth dilution method in 96-well plates was employed to determine the minimum inhibitory concentration (MIC) of synthesized compounds (which was taken into the 8% of MeCN in Water solution). Phosphate saline buffer (PBS) was utilized for sequential dilution of the working concentrations. A bacterial suspension of 100 µL with an A_{600nm} of 0.01 was combined with 100 µL of the prepared working concentration in the 96-well plate. The growth curve of the bacteria was monitored using a microplate reader (Eppendorf AF2200) equipped with a shaker, maintained at 37°C, for a duration of 16 hours. Optical density readings at 600 nm were taken at 10-minute intervals during a kinetic cycle, with concurrent shaking. The MIC, the lowest concentration at which the growth curve exhibited a 95% decline, was determined based on these measurements.






Figure S2. Evaluation of antibacterial efficacy of various C1-Substituted Tetrahydroisoquinoline (THIQ) Motifs. Growth kinetic curve of MRSA in presence of those derivatives.

5. Recyclability test for Catalyst

To check the recyclability of WS₂ QD catalyst, WS₂ QD catalyst were extracted into aqueous layer (10ml) against EtOAc layer (10ml) after the completion of reaction. The extracted aqueous layer was subsequently utilized as the reaction solvent for the next cycle. The combined organic layer was dried over anhydrous Na₂SO₄, concentrated to afford the residue and submitted for NMR. Reaction yield was determined by NMR against internal standard Terephthalaldehyde.

Table S3. Recyclability test for Catalyst.

Cycle	1	2	3	4	5
Yield (%)	82	81	79	78	75
Condition: Reactions were carried out on 0.5 mmol scale of 1a. Yield and selectivity were determined by crude NMR against Terephthalaldehyde as internal standard.					





Figure S4. TEM image of recycled QD after 5th cycle.

6. Unsuccessful Substates



7. General Procedure for synthesis of C1 substituted THIQ

All Substrates were synthesised with standard optimized reaction conditions of 0.5 mmol of N-Ph THIQ with 0.75 mmol of Nucleophile (Naphthol, Indole, Pyrrole, or Phosphite) under catalytic loading of 5 w/w% WS₂ QD in 2ml of H₂O solvent inside Schlenk tube under Blue LED irradiation at room

temperature under oxygen atmosphere. After 24h of reaction, reaction mixture was portioned between water layer (30 mL) and EtOAc layer (30 mL). The aqueous layer was extracted with EtOAc (30 mL x 3 times) and the combined organic phase was washed with a saturated solution of brine (30 mL), the combined organic layer was dried over anhydrous Na₂SO₄, concentrated to afford the residue. The crude product was purified by column chromatography on silica gel using Pet. Ether / EtOAc as the eluent.

8. Procedure for reaction scale up


Reaction was scale up with same general procedure 7 under optimized reaction condition by increasing the loading of all reaction component (Nucleophile, Catalyst, Solvent) proportionally to the mmol of starting material N-Ph THIQ under Blue light irradiation at room temperature under oxygen atmosphere for 24h.

9. Photograph of reaction setup



10. Characterization of substrates

6-bromo-1-(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)naphthalen-2-ol (3a)



Purification: by column chromatography (Pet.ether/EtOAc = 96/04)


R_f (Pet. ether /EtOAc = 85/15): 0.6

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 11.14 (bs, 1H), 8.10 – 8.08 (m, 1H), 7.90 – 7.89 (m, 1H), 7.65 – 7.63 (m, 1H), 7.52 – 7.49 (m, 1H), 7.32 – 7.30 (m, 2H), 7.23 – 7.15 (m, 4H), 7.04 – 6.93 (m, 3H), 6.68 – 6.66 (m, 1H), 6.37 (s, 1H), 3.73 – 3.69 (m, 1H), 3.66 – 3.58 (m, 1H), 3.46 – 3.39 (m, 1H), 3.06 – 3.02 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 155.04, 149.84, 135.98, 133.43, 132.16, 130.89, 130.30, 129.62, 129.19, 128.71, 128.47, 127.35, 126.88, 126.58, 125.78, 123.17, 122.91, 120.89, 118.73, 116.02, 59.63, 55.28, 30.57.

HRMS (ESI) m/z: $[M+H]^+$ Calcd for $C_{25}H_{20}BrNOH$ 430.0806; Found: 430.0808

7-bromo-1-(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)naphthalen-2-ol (3b)



Purification: by column chromatography (Pet.ether/EtOAc = 96/04)


R_f (Pet. ether /EtOAc = 85/15): 0.6

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 11.18 (bs, 1H), 8.36 (s, 1H), 7.61 – 7.55 (m, 2H), 7.43 – 7.40 (m, 1H), 7.33 – 7.31 (m, 2H), 7.23 – 7.16 (m, 4H), 7.05 – 6.94 (m, 3H), 6.70 – 6.68 (m, 1H), 6.31 (s, 1H), 3.73 – 3.68 (m, 1H), 3.65 – 3.57 (m, 1H), 3.46 – 3.39 (m, 1H), 3.06 – 3.02 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 155.58, 149.80, 135.88, 134.95, 133.46, 130.65, 129.59, 129.22, 128.47, 127.42, 126.91, 126.77, 126.62, 125.91, 125.80, 123.26, 123.21, 121.86, 120.15, 117.76, 59.65, 55.38, 30.55.

HRMS (ESI) m/z: $[M+H]^+$ Calcd for $C_{25}H_{20}BrNOH$ 430.0806; Found: 430.0804

7-methoxy-1-(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)naphthalen-2-ol (3c)



Purification: by column chromatography (Pet.ether/EtOAc = 96/03)


R_f (Pet. ether /EtOAc = 85/15): 0.6

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 10.96 (bs, 1H), 7.64 – 7.61 (m, 1H), 7.50 – 7.48 (m, 2H), 7.30 – 7.25 (m, 2H), 7.20 – 7.11 (m, 4H), 7.01 – 6.92 (m, 3H), 6.77 – 6.75 (m, 2H), 6.30 (s, 1H), 3.96 (s, 3H), 3.73 – 3.69 (m, 1H), 3.64 – 3.55 (m, 1H), 3.44 – 3.37 (m, 1H), 3.03 – 2.99 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 159.02, 155.26, 150.01, 136.40, 134.85, 133.44, 130.57, 129.34, 129.08, 128.37, 127.45, 126.74, 126.60, 125.47, 123.91, 123.02, 117.74, 117.13, 114.14, 100.81, 59.61, 55.44, 30.61.

HRMS (ESI) m/z: $[M+H]^+$ Calcd for $C_{26}H_{23}NO_2H$ 382.1807; Found: 382.1804

1-(7-methyl-1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3d)



Purification: by column chromatography (Pet.ether/EtOAc = 94/06)

R_f (Pet. ether /EtOAc = 85/15): 0.6


¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.86 (bs, 1H), 7.46 - 7.46 (m, 1H), 7.35 - 7.20 (m, 6H), 7.09 - 7.02 (m, 4H), 6.86 - 6.82 (m, 1H), 6.66 (s, 1H), 6.23 (s, 1H), 3.69 - 3.66 (m, 2H), 3.17 - 3.09 (m, 1H), 2.90 - 2.86 (m, 1H), 2.47 (s, 3H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 149.81, 137.50, 136.16, 135.57, 129.25, 128.83, 128.08, 126.72, 126.03, 125.78, 123.95, 122.67, 120.27, 119.90, 119.66, 118.10, 117.80, 115.83, 56.81, 42.37, 26.78, 16.63.

DEPT: +ve: 129.25, 128.83, 128.08, 126.72, 125.78, 123.95, 122.67, 119.90, 118.10, 117.80, 115.83, 56.81, 16.63.; -ve: 42.37, 26.78

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₂₂N₂H 339.1861; Found: 339.1865

3-(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-1H-indole-7-carbaldehyde (3e)



Purification: by column chromatography (Pet.ether/EtOAc = 95/05)

R_f (Pet. ether /EtOAc = 90/10): 0.4


¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 10.10 (s, 1H), 9.96 (bs, 1H), 7.82 - 7.81 (m, 1H), 7.64 - 7.63 (m, 1H), 7.30 - 7.16 (m, 7H), 7.08 - 7.07 (m, 2H), 6.86 - 6.79 (m, 2H), 6.22 (s, 1H), 3.64 - 3.61 (m, 2H), 3.12 - 3.11 (m, 1H), 2.86 - 2.82 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 193.52, 136.93, 135.43, 134.41, 129.30, 129.03, 128.93, 128.00, 127.077, 127.67, 126.95, 126.02, 125.87, 120.34, 119.35, 118.69, 116.45, 56.78, 42.42, 26.66.

DEPT: +ve: 193.52, 129.30, 129.03, 128.93, 128.00, 127.077, 126.95, 125.87, 119.35, 118.69, 116.45, 56.78.; -ve: 42.42, 26.66.

HRMS (ESI) m/z: NA

1-(6-methyl-1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3f)



Purification: by column chromatography (Pet.ether/EtOAc = 96/04)

R_f (Pet. ether /EtOAc = 90/10): 0.5


¹H NMR (400 MHz, , Chloroform – *d*): δ (ppm) 7.80 (bs, 1H), 7.48 - 7.46 (m, 1H), 7.35 – 7.20 (m, 6H), 7.10 – 7.08 (m, 3H), 6.94 – 6.84 (m, 2H), 6.55 (s, 1H), 6.21 (s, 1H), 3.67 – 3.66 (m, 2H), 3.17 – 3.09 (m, 1H), 2.90 – 2.86 (m, 1H), 2.48 (s, 3H).

¹³C NMR (100 MHz, Chloroform – *d*): δ (ppm) 149.80, 137.54, 137.07, 135.54, 131.91, 131.05, 129.27, 128.83, 128.08, 126.72, 125.77, 124.34, 123.69, 121.42, 119.69, 118.17, 115.89, 111.13, 56.84, 42.36, 26.77, 21.72.

DEPT: +ve: 129.27, 128.83, 128.08, 126.72, 125.77, 123.69, 121.42, 119.69, 118.17, 115.89, 111.13, 56.84, 21.72.; -ve: 42.36, 26.77.

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₂₂N₂H 339.1861; Found: 339.1863

1-(6-chloro-1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3g)



Purification: by column chromatography (Pet.ether/EtOAc = 95/05)

R_f (Pet. ether /EtOAc = 90/10): 0.5


¹H NMR (400 MHz, , Chloroform – *d*): δ (ppm) 8.00 (bs, 1H), 7.43 - 7.41 (m, 1H), 7.29 – 7.18 (m, 7H), 7.06 – 6.99 (m, 3H), 6.86 – 6.82 (m, 1H), 6.62 (s, 1H), 6.14 (s, 1H), 3.63 – 3.61 (m, 2H), 3.13 – 3.06 (m, 1H), 2.87 – 2.80 (m, 1H).

¹³C NMR (100 MHz, Chloroform – *d*): δ (ppm) 136.92, 135.46, 129.28, 128.94, 128.02, 127.98, 126.85, 125.81, 125.09, 124.85, 121.01, 120.37, 118.52, 116.21, 110.98, 56.67, 42.40, 26.64.

DEPT: +ve: 129.28, 128.94, 127.98, 126.85, 125.81, 124.85, 121.01, 120.37, 118.52, 116.21, 110.98, 56.67.; -ve: 42.40, 26.64.

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₁₉ClN₂H 359.1315; Found: 359.1316

3-(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-1H-indole-5-carbonitrile (3h)



Purification: by column chromatography (Pet.ether/EtOAc = 85/15)

R_f (Pet. ether /EtOAc = 80/20): 0.3

¹H NMR (400 MHz, DMSO – *d*₆): δ (ppm) 11.55 (bs, 1H), 7.89 (s, 1H), 7.51 – 7.49 (m, 1H), 7.40 – 7.38 (m, 2H), 7.19 – 7.17 (m, 5H), 7.03 – 7.03 (m, 3H), 6.72 – 6.70 (m, 1H), 6.31 (s, 1H), 3.54 – 3.43 (m, 2H), 3.05 – 2.88 (m, 2H).

¹³C NMR (100 MHz, DMSO – *d*₆): δ (ppm) 149.60, 138.69, 137.78, 135.34, 129.51, 128.98, 128.17, 127.50, 127.14, 126.24, 126.19, 125.33, 124.19, 121.28, 115.58, 113.40, 102.56, 101.10, 55.73, 42.33, 27.03.

DEPT: +ve: 129.51, 128.98, 128.17, 127.50, 127.14, 126.24, 125.33, 124.19, 115.58, 113.40, 55.73.

-ve: 42.33, 27.03.

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₁₉N₃H 350.1657; Found: 350.1660

dimethyl(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phosphonate (3i)



Purification: by column chromatography (Pet.ether/EtOAc = 68/32)

R_f (Pet. ether /EtOAc = 50/50): 0.4

¹H NMR (400 MHz, , Chloroform – *d*): δ (ppm) 7.38 – 7.37 (m, 1H), 7.30 – 7.17 (m, 5H), 7.01 – 6.99 (m, 2H), 6.85 – 6.81 (m, 1H), 5.22 (d, J = 20.01 Hz, 1H), 4.12 – 4.00 (m, 2H), 3.69 – 3.65 (m, 6H), 3.12 – 3.02 (m, 2H).


¹³C NMR (100 MHz, Chloroform – *d*): δ (ppm) 136.45, 130.93, 129.27, 128.85, 127.99, 127.94, 127.59, 127.56, 126.10, 126.07, 118.72, 114.81, 58.77 (d, J = 159.59 Hz, 1C), 54.00, 53.93, 53.0152.94, 43.58, 26.68.

DEPT: +ve: 130.93, 129.27, 128.85, 127.99, 127.94, 127.59, 127.56, 126.10, 126.07, 118.72, 114.81, 58.77 (d, J = 159.59 Hz, 1C), 54.00, 53.93, 53.0152.94.; -ve: 43.58, 26.68.

³¹P NMR (162 MHz, Chloroform – *d*): δ (ppm) 24.36.

HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₇H₂₀NO₃PNa 340.1079; Found: 340.1078

diethyl (2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phosphonate (3j)



Purification: by column chromatography (Pet.ether/EtOAc = 70/30)

R_f (Pet. ether /EtOAc = 50/50): 0.5

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.30 – 7.28 (m, 1H), 7.18 – 7.15 (m, 2H), 7.10 – 7.07 (m, 2H), 6.91 – 6.89 (m, 2H), 6.72 – 6.69 (m, 1H), 5.11 (d, J = 20.07 Hz, 1H), 4.02 – 3.80 (m, 5H), 3.57 – 3.51 (m, 1H), 3.02 – 2.88 (m, 2H), 1.16 (t, J = 6.96 Hz, 3H), 1.05 (t, J = 7.05 Hz, 3H).


¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 149.51, 149.45, 136.55, 136.50, 130.73, 129.22, 128.84, 128.82, 128.24, 128.19, 127.53, 127.50, 125.96, 125.94, 118.55, 114.88, 63.43, 63.36, 62.46, 62.38, 58.91 (d, J = 159.19 Hz, 1C), 43.56, 26.85, 16.56, 16.50, 16.48, 16.42.

DEPT: +ve: 129.22, 128.84, 128.82, 128.24, 128.19, 127.53, 127.50, 125.96, 125.94, 118.55, 114.88, 58.91 (d, J = 159.19 Hz, 1C), 16.56, 16.50, 16.48, 16.42.; -ve: 63.43, 63.36, 62.46, 62.38, 43.56, 26.85.

³¹P NMR (162 MHz, Chloroform - *d*): δ (ppm) 22.15.

HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₉H₂₄NO₃PNa 368.1392; Found: 368.1391

dibenzyl(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phosphonate (3k)



Purification: by column chromatography (Pet.ether/EtOAc = 82/18)

R_f (Pet. ether /EtOAc = 80/20): 0.2

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.40 - 7.37 (m, 1H), 7.35 – 7.32 (m, 3H), 7.30 – 7.24 (m, 8H), 7.20 – 7.14 (m, 4H), 7.02 – 7.00 (m, 2H), 6.85 – 6.82 (m, 1H), 5.33 (d, J = 19.61 Hz, 1H), 5.07 – 5.03 (m, 1H), 4.99 – 4.89 (m, 2H), 4.83 – 4.79 (m, 1H), 4.09 – 4.03 (m, 1H), 3.69 – 3.63 (m, 1H), 3.15 – 2.98 (m, 2H).


¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 130.39, 129.23, 128.85, 128.82, 128.47, 128.38, 128.29, 128.23, 128.19, 128.07, 128.02, 127.60, 127.57, 126.03, 126.00, 118.65, 114.90, 68.71, 68.64, 67.81, 67.73, 59.05 (d, J = 158.09 Hz, 1C), 43.59, 26.85.

DEPT: +ve: 129.23, 128.85, 128.82, 128.47, 128.38, 128.29, 128.23, 128.19, 128.07, 128.02, 127.60, 127.57, 126.03, 126.00, 118.65, 114.90, 59.05 (d, J = 158.09 Hz, 1C).; -ve: 68.71, 68.64, 67.81, 67.73, 43.59, 26.85.

³¹P NMR (162 MHz, Chloroform - *d*): δ (ppm) 22.96.

HRMS (ESI) m/z: NA

2,5-bis(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-1H-pyrrole (3l)



Purification: by column chromatography (Pet.ether/EtOAc = 96/03)

R_f (Pet. ether /EtOAc = 90/10): 0.7


¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.84 (d, *J* = 11.95 Hz, 1H), 7.28 – 7.19 (m, 10H), 7.14 – 7.13 (m, 2H), 6.94 – 6.90 (m, 4H), 6.86 – 6.83 (m, 2H), 5.79 (d, *J* = 9.01 Hz, 2H), 5.52 (s, 1H), 5.45 (s, 1H), 3.52 – 3.44 (m, 2H), 3.38 – 3.24 (m, 2H), 3.00 – 2.93 (m, 2H), 2.74 – 2.66 (m, 2H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 150.07, 149.99, 135.67, 135.07, 135.05, 132.69, 132.58, 129.30, 129.23, 128.73, 128.68, 127.83, 126.93, 125.78, 125.74, 119.13, 119.05, 116.36, 116.25, 107.67, 107.53, 57.85, 57.80, 42.71, 42.38, 27.24, 27.20.

DEPT: +ve: 129.30, 129.23, 128.73, 128.68, 127.83, 126.93, 125.78, 125.74, 119.13, 119.05, 116.36, 116.25, 107.67, 107.53, 57.85, 57.80.; -ve: 42.71, 42.38, 27.24, 27.20.

HRMS (ESI) m/z: [M]⁺ Calcd for C₃₄H₃₁N₃ 481.2518; Found: 481.2495

1-(5-bromo-1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3m)



Purification: by column chromatography (Pet.ether/EtOAc = 95/05)


R_f (Pet. ether /EtOAc = 90/10): 0.5

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.97 (bs, 1H), 7.59 (s, 1H), 7.24 – 7.13 (m, 8H), 7.00 – 6.98 (m, 2H), 6.82 – 6.78 (m, 1H), 6.61 (s, 1H), 6.06 (s, 1H), 3.59 – 3.52 (m, 2H), 3.08 – 3.00 (m, 1H), 2.81 – 2.76 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 149.81, 136.95, 135.39, 135.13, 129.17, 128.87, 128.08, 127.91, 126.78, 125.77, 125.34, 124.97, 122.65, 119.01, 118.73, 116.46, 112.95, 112.40, 56.65, 42.51, 26.55.

HRMS (ESI) m/z: NA

1-(5-methoxy-1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3n)



Purification: by column chromatography (Pet.ether/EtOAc = 95/05)


R_f (Pet. ether /EtOAc = 90/10): 0.5

¹H NMR (400 MHz, , Chloroform – *d*): δ (ppm) 7.81 (bs, 1H), 7.27 – 7.25 (m, 1H), 7.22 – 7.14 (m, 6H), 7.02 – 7.00 (m, 2H), 6.87 – 6.86 (m, 1H), 6.80 – 6.74 (m, 2H), 6.57 – 6.56 (m, 1H), 6.13 (s, 1H), 3.64 (s, 3H), 3.60 – 3.57 (m, 2H), 3.10 – 3.02 (m, 1H), 2.83 – 2.77 (m, 1H).

¹³C NMR (100 MHz, Chloroform – *d*): δ (ppm) 153.83, 149.97, 137.47, 135.51, 131.55, 129.13, 128.73, 127.94, 126.88, 126.63, 125.62, 124.92, 118.69, 118.22, 116.15, 112.21, 111.58, 101.84, 56.79, 55.62, 42.07, 26.89.

HRMS (ESI) m/z: NA

1-(1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3o)



Purification: by column chromatography (Pet.ether/EtOAc = 95/05)


R_f (Pet. ether /EtOAc = 90/10): 0.4

¹H NMR (400 MHz, , Chloroform – *d*): δ (ppm) 7.99 (bs, 1H), 7.61 - 7.59 (m, 1H), 7.34 – 7.27 (m, 4H), 7.24 – 7.17 (m, 4H), 7.09 – 7.07 (m, 3H), 6.85 – 6.81 (m, 1H), 6.64 (s, 1H), 6.22 (s, 1H), 3.68 – 3.65 (m, 2H), 3.15 – 3.07 (m, 1H), 2.87 – 2.83 (m, 1H).

¹³C NMR (100 MHz, Chloroform – *d*): δ (ppm) 149.80, 137.43, 136.61, 135.58, 129.26, 128.86, 128.08, 126.72, 126.47, 125.75, 124.28, 122.10, 120.06, 119.63, 119.16, 118.13, 115.83, 111.84, 56.68, 42.31, 26.65.

HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₀N₂H 325.1704; Found: 325.1703

1-(2-methyl-1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3p)



Purification: by column chromatography (Pet.ether/EtOAc = 95/05)


R_f (Pet. ether /EtOAc = 90/10): 0.5

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.72 (bs, 1H), 7.29 (s, 1H), 7.22 – 7.18 (m, 4H), 7.11 – 7.03 (m, 6H), 6.95 – 6.91 (m, 1H), 6.88 – 6.85 (m, 1H), 6.00 (s, 1H), 3.75 – 3.61 (m, 2H), 3.16 – 3.00 (m, 2H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 150.92, 138.02, 135.29, 134.91, 133.27, 128.77, 128.67, 128.59, 128.19, 126.24, 126.02, 120.75, 120.18, 119.47, 119.42, 119.16, 113.44, 109.96, 57.13, 45.87, 27.95, 12.25.

HRMS (ESI) m/z: NA

1-(1-methyl-1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3q)



Purification: by column chromatography (Pet.ether/EtOAc = 97/03)


R_f (Pet. ether /EtOAc = 90/10): 0.4

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.61 - 7.59 (m, 1H), 7.36 – 7.34 (m, 1H), 7.31 – 7.27 (m, 4H), 7.25 – 7.21 (m, 3H), 7.09 – 7.07 (m, 3H), 6.85 – 6.81 (m, 1H), 6.56 (s, 1H), 6.24 (s, 1H), 3.76 – 3.65 (m, 2H), 3.70 (s, 3H), 3.16 – 3.09 (m, 1H), 2.90 – 2.84 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 149.74, 137.60, 137.35, 135.54, 129.21, 128.80, 128.03, 126.87, 126.62, 125.69, 121.64, 119.11, 117.99, 117.61, 115.65, 109.13, 56.60, 42.18, 32.69, 26.61.

HRMS (ESI) m/z: NA

1-(6-fluoro-1H-indol-3-yl)-2-phenyl-1,2,3,4-tetrahydroisoquinoline (3r)



Purification: by column chromatography (Pet.ether/EtOAc = 94/06)


R_f (Pet. ether /EtOAc = 90/10): 0.4

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.95 (bs, 1H), 7.22 – 7.11 (m, 8H), 7.01 – 6.99 (m, 2H), 6.90 – 6.85 (m, 1H), 6.80 – 6.76 (m, 1H), 6.66 (s, 1H), 6.07 (s, 1H), 3.62 – 3.53 (m, 2H), 3.09 – 3.01 (m, 1H), 2.80 – 2.76 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 149.73, 137.05, 136.92, 135.46, 129.21, 128.90, 128.03, 127.93, 126.78, 125.73, 125.07, 124.74, 121.04, 120.35, 119.45, 118.51, 116.20, 110.89, 56.64, 42.38, 26.63.

HRMS (ESI) *m/z*: NA

1-(1H-indol-3-yl)-2-(3-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (3s)



Purification: by column chromatography (Pet.ether/EtOAc = 93/07)


R_f (Pet. ether /EtOAc = 90/10): 0.2

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 7.92 (bs, 1H), 7.54 - 7.52 (m, 1H), 7.33 - 7.30 (m, 3H), 7.24 - 7.14 (m, 6H), 7.07 - 6.98 (m, 2H), 6.66 - 6.65 (m, 1H), 6.20 (s, 1H), 3.71 - 3.62 (m, 2H), 3.11 - 3.03 (m, 1H), 2.90 - 2.84 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 149.66, 136.91, 136.60, 135.21, 129.68, 128.81, 127.96, 126.97, 126.14, 125.92, 124.11, 122.26, 119.78, 118.51, 118.02, 114.13, 111.36, 111.32, 111.17, 56.55, 42.21, 26.67.

HRMS (ESI) *m/z*: NA

1-(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)naphthalen-2-ol (3t)



Purification: by column chromatography (Pet.ether/EtOAc = 97/03)


R_f (Pet. ether /EtOAc = 85/15): 0.6

¹H NMR (400 MHz, , Chloroform - *d*): δ (ppm) 11.09 (bs, 1H), 8.23 - 8.21 (m, 1H), 7.77 - 7.75 (m, 1H), 7.62 - 7.57 (m, 2H), 7.37 - 7.33 (m, 3H), 7.23 - 7.14 (m, 4H), 7.02 - 6.92 (m, 3H), 6.74 - 6.72 (m, 1H), 6.45 (s, 1H), 3.76 - 3.72 (m, 1H), 3.68 - 3.60 (m, 1H), 3.47 - 3.40 (m, 1H), 3.06 - 3.02 (m, 1H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 154.62, 149.86, 136.30, 133.62, 133.38, 129.62, 129.12, 129.03, 128.44, 128.37, 127.53, 127.21, 126.74, 126.54, 125.61, 123.13, 122.55, 121.03, 119.66, 118.37, 59.51, 55.45, 30.60.

HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₅H₂₁NOH 352.1701; Found: 352.1700

diisopropyl(2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)phosphine oxide (3u)



Purification: by column chromatography (Pet.ether/EtOAc = 65/35)

R_f (Pet. ether /EtOAc = 50/50): 0.4


¹H NMR (400 MHz, Chloroform - *d*): δ (ppm) 7.43 – 7.42 (m, 1H), 7.27 – 7.14 (m, 5H), 6.99 – 6.97 (m, 2H), 6.81 – 6.78 (m, 1H), 5.17 (d, *J* = 21.15 Hz, 1H), 4.69 – 4.61 (m, 2H), 4.10 – 4.03 (m, 1H), 3.71 – 3.65 (m, 1H), 3.05 – 2.99 (m, 2H), 1.33 (d, *J* = 6.65 Hz, 6H), 1.19 (d, *J* = 6.61 Hz, 3H), 0.97 (d, *J* = 6.62 Hz, 3H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 149.56, 149.50, 139.23, 136.42, 136.37, 135.13, 130.88, 128.96, 128.69, 128.67, 128.42, 128.37, 127.26, 127.23, 125.61, 125.58, 118.27, 115.04, 114.02, 72.29, 72.21, 70.93, 70.85, 58.73 (d, *J* = 161.38 Hz, 1C), 43.47, 26.55, 24.55, 24.52, 24.10, 24.07, 23.72, 23.66, 23.29, 23.24.

³¹P NMR (162 MHz, Chloroform - *d*): δ (ppm) 20.15.

HRMS (ESI) m/z: NA

2-phenyl-3,4-dihydroisoquinolin-1(2H)-one (4a)





Purification: by column chromatography (Pet.ether/EtOAc = 90/10)



R_f (Pet. ether /EtOAc = 80/20): 0.5


¹H NMR (400 MHz, Chloroform - *d*): δ (ppm) 8.19 – 8.17 (m, 1H), 7.51 – 7.38 (m, 6H), 7.29 – 7.26 (m, 2H), 4.02 (t, *J* = 6.45 Hz, 2H), 3.17 (t, *J* = 6.47 Hz, 2H).

¹³C NMR (100 MHz, Chloroform - *d*): δ (ppm) 164.22, 143.13, 138.32, 132.05, 129.74, 128.93, 128.77, 127.21, 126.96, 126.27, 125.34, 49.44, 28.65.



11. NMR and HRMS copies









^1H (400 MHz, CDCl_3)





$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)







^1H (400 MHz, CDCl_3)






$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)







DEPT (100 MHz, CDCl₃)













^1H (400 MHz, CDCl_3)





$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)







DEPT (100 MHz, CDCl₃)







^1H (400 MHz, CDCl_3)




$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)








— 11.554




^1H (400 MHz, DMSO - d₆)





$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, DMSO - d₆)







DEPT (100 MHz, DMSO - d6)







^1H (400 MHz, CDCl_3)





$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)







DEPT (100 MHz, CDCl₃)





³¹P{¹H} (162 MHz, CDCl₃)






3j


^1H (400 MHz, CDCl_3)





3j

$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)









DEPT (100 MHz, CDCl₃)





³¹P{¹H} (162 MHz, CDCl₃)









DEPT (100 MHz, CDCl₃)





³¹P{¹H} (162 MHz, CDCl₃)







¹H (400 MHz, CDCl₃)



¹³C{¹H} (100 MHz, CDCl₃)





DEPT (100 MHz, CDCl₃)









^1H (400 MHz, CDCl_3)



$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)










3o

^1H (400 MHz, CDCl_3)





3o

$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)







^1H (400 MHz, CDCl_3)





$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)






3q





^1H (400 MHz, CDCl_3)







3q


$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)













3u



$^{31}\text{P}\{^1\text{H}\}$ (162 MHz, CDCl_3)






4a

^1H (400 MHz, CDCl_3)



4a


$^{13}\text{C}\{^1\text{H}\}$ (100 MHz, CDCl_3)



JPD-473
24032021_04 89 (0.839) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (89-(1:24+408:435))

IISc Organic Chemistry


24-Mar-2021
1: TOF MS ES+
1.13e6



JPD-476
24032021_05 87 (0.822) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (87-(1:19+405:430))

IISc Organic Chemistry


24-Mar-2021
1: TOF MS ES+
2.19e5



JPD-502
01092021_03 111 (1.028) AM2 (Ar,22000,0,556,28,0,00,LS 10); ABS; Cm (111-(1:37+405:436))

IISc Organic Chemistry


01-Sep-2021
1: TOF MS ES+
6.11e5



JPD-805
21092023_40 59 (0.562) AM2 (Ar,22000,0,556,28,0,00,LS 10); ABS; Cm (59-408:415)


IISc Organic Chemistry

21-Sep-2023
1: TOF MS ES+
3.03e4




JPD-809
21092023_37 66 (0.622) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (66-401:411)

21-Sep-2023
1: TOF MS ES+
2.78e4



JPD-810
21092023_36 61 (0.579) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (61-117+398:409)


21-Sep-2023
1: TOF MS ES+
2.37e4



JPD-806
21092023_34 62 (0.588) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (62-(1:7+413:420))

IISc Organic Chemistry


21-Sep-2023
1: TOF MS ES+
1.45e4



JPD-819
21092023_41 75 (0.719) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (75-377:385)


IISc Organic Chemistry

21-Sep-2023
1: TOF MS ES+
1.47e4




JPD-822 IISc Organic Chemistry
21092023_35 65 (0.614) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (65-(3:12+404:416))

21-Sep-2023
1: TOF MS ES+
2.88e5




JPD-598 IISc Organic Chemistry
01042022_12 70 (0.657) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (69:75-(1:19+409:430))

01-Apr-2022
1: TOF MS ES+
3.54e5



JPD-861 IISc Organic Chemistry
25092023_32 63 (0.597) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (63-(1:16+418:435))

25-Sep-2023
1: TOF MS ES+
9.18e5



JPD-862 IISc Organic Chemistry
25092023_33 67 (0.631) AM2 (Ar,22000.0,556.28,0.00,LS 10); ABS; Cm (67-(1:16+426:435))

25-Sep-2023
1: TOF MS ES+
1.46e6

